摘要
同步放化疗(CRCT)是近年发展起来的肿瘤综合治疗的一种新模式,不可手术的局部晚期非小细胞肺癌(NSCLC)患者约占45%,CRCT是不可切除的局部晚期NSCLC的标准治疗,以铂类为基础的化疗与同步胸腔放疗使局部晚期NSCLC患者5年生存率接近15%,但局部复发及远处转移仍是治疗失败的主要原因。为进一步提高局部晚期NSCLC疗效,国内外对CRCT进行了广泛的研究,并取得一定疗效,但对CRCT的最佳治疗模式仍存有许多争议,同时靶向治疗与CRCT的联合成了新的热点。现就近年来局部晚期NSCLC CRCT临床研究进展作一综述。
Lung cancer remains the leading cause of cancer death in the worldwide. Approximately 45% of patients present with stage III disease. For patients with unresectable stage IIIA/B disease, Several clinical trials demonstrated concurrent chemoradiotherapy was superior to TRT alone and sequential chemoradiotherapy. Chemoradiotherapy is a standard treatment for unresectable locally advanced nonsmall cell lung cancer （ NSCLC）, Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced NSCLCo Despite a substantial number of clinical trials, The most effective chemotherapy combination, the use of induction or consolidation chemotherapy in addition to the concurrent portion of therapy, and the optimal dose of chemotherapy with concurrent TRT have yet to be determined. In addition to evaluating optimal sequencing strategies of combined modality therapy, current investigations are also focusing on the integration of novel agents, including chemotherapeutic and targeted therapies. Currently ongoing trials involving novel approaches are reviewed here.
出处
《医学研究生学报》
CAS
2007年第11期1206-1210,共5页
Journal of Medical Postgraduates
基金
江苏省自然科学基金前期预研项目(BK2005203)
全军医学科学技术研究"十一五"计划课题资助项目(批准号:06MA111)
南京市医学发展重点项目(zkx0427)
关键词
非小细胞肺癌
化疗
胸腔放疗
同步放化疗
Non-small cell lung cancer
Chemotherapy
Thoracic radiation
Concurrent radiochemotherapy
